Harvard Bioscience (HBIO) EBT Margin (2010 - 2026)

Harvard Bioscience (HBIO) has reported EBT Margin for 17 consecutive years, with 12.74% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT Margin fell 172.0% year-over-year to 12.74% in Q2 2026; TTM through Jun 2026 was 12.0%, a 5216.0% increase from a year earlier, with the FY2025 full-year figure at 66.3%, down 5391.0% from the prior year.
• EBT Margin was 12.74% for Q2 2026 at Harvard Bioscience, up from 15.93% in the prior quarter.
• Over five years, EBT Margin peaked at 11.71% in Q2 2022 and troughed at 233.28% in Q1 2025.
• A 5-year average of 21.4% and a median of 11.88% in 2025 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin sank 21499 bps in 2025 and soared 21734 bps in 2026, its largest moves.
• Over 5 years, EBT Margin stood at 3.14% in 2022, then slipped by 25 bps to 3.92% in 2023, then jumped by 161 bps to 2.4% in 2024, then plunged by 662 bps to 13.5% in 2025, then advanced by 6 bps to 12.74% in 2026.
• The last three EBT Margin figures came in at 12.74% (Q2 2026), 15.93% (Q1 2026), and 13.5% (Q4 2025), per Business Quant data.